LUDOCARE is a company founded in 2017 and located in Lyon, FRANCE, specializing in digital therapies for children with chronic illnesses. Its mission is to improve the life trajectory of young patients through innovative, personalized digital solutions. By supporting children from an early age, LUDOCARE helps them to adopt the right reflexes, manage their treatments and acquire a full autonomy for an optimal control of their disease.
To answer the specific needs of pediatric asthma, the company has developed an innovative digital medical device: JOE digital therapy, designed for 3 to 11 yrs old children suffering from persistent asthma. This device acts on the main challenges encountered by these patients, such as lack of compliance and errors in the use of medical devices. By educating children in good practices and optimizing treatment effectiveness, JOE helps to significantly improve their quality of life.
Joe being used in real-life situation, by Ludocare.
Ludocare has been collaborating with Benkei for many years and at several levels, for a true multifactorial approach :
- Since 2018, Benkei helps Ludocare in securing its fiscal advantages. Thanks to the CIR and CII obtained each year for its research activities, Ludocare can pursue its developments.
- In 2019, Ludocare and Benkei are working on a strategic project: the i-Lab grant, obtained in June 2019, which enabled Ludocare to develop its product into its first medical device version and to conduct an observational study. This study confirmed the added value of the JOE solution for families, and enabled Ludocare to draw on solid data to build its clinical strategy.
- In 2022, Ludocare raises €4.2M to finance its clinical study. As part of its ambition to make its innovation available to all, Ludocare is aiming to have its medical services covered by the French health insurance system. To achieve this, in September 2022, Ludocare launches a multicenter randomized clinical trial to assess the efficacy and safety of patients learning to self-manage the treatments prescribed and dispensed by JOE, on the number of severe exacerbations in children with asthma classified as 2, 3, 4 or 5 according to the GINA classification.
- In 2024, still with the support of Benkei, Ludocare wins the i-Nov competition, to accelerate its development and define and develop a new scalable service infrastructure to support the expansion of the user base, while maintaining a high level of availability, robustness, security and controlling infrastructure costs. In addition, the integration and analysis of external environmental data, coupled with compliance data, will enable us to add a preventive dimension to the solution, and to design the JOE robot of tomorrow: its hardware has been entirely redesigned with eco-responsibility, CSR and scaling in mind.
« Our collaboration with Benkei has been key to the development of both our solution and our company. At each step of our company growth, we have been able to count on Benkei to understand our needs, align project schedules and apply for public funding, enabling us to achieve our development objectives while optimizing the financing of our activities ».
Alexandra de la Fontaine, CEO & Co-Founder of Ludocare. 